Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: Product/Service

Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile

Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a clinical stage oncology company, today presented results from a Phase 1 study with CYT-0851 in combination with capecitabine or gemcitabine in a poster titled "Phase 1 Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors" (Abstract: 3099, Poster: 297) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois.

"We are encouraged by the preliminary data from the Phase 1 dose escalation study with CYT-0851 in combination with capecitabine and gemcitabine and are pleased that the safety profile of CYT-0851 continues to be generally tolerable even when combined with these standard chemotherapy agents," said Markus Renschler, MD, President and Chief Executive Officer of Cyteir. "The Cyteir team is diligently executing on the clinical development of CYT-0851 as a potential combination therapy, and we look forward to sharing preliminary data for all patients in these cohorts mid-year."

Phase 1 Study Objectives

The primary objective of the ongoing Phase 1 study is to determine the recommended Phase 2 dose and maximum tolerated dose of CYT-0851 in combination with capecitabine or gemcitabine. Key secondary objectives include evaluation of safety and tolerability, determination of the pharmacokinetic parameters, optimal dosing regimen for each combination and characterization of preliminary anti-tumor activity of the combinations.

Phase 1 Study Preliminary Findings

The data presented in the poster are the first report of preliminary results of an ongoing study.

As of the May 1, 2023 data cutoff, 22 patients were enrolled in the capecitabine cohort across four dose-escalation cohorts from 100 mg to 400 mg once daily dose and 13 patients were enrolled in the gemcitabine cohort across three dose-escalation cohorts from 100 mg to 300 mg once daily dose. Fourteen patients in the capecitabine arm were response evaluable and eight patients in the gemcitabine arm were response evaluable.

The recommended Phase 2 dose in the capecitabine combination is 400 mg once a day with no dose limiting toxicities observed. The maximum tolerated dose in the combination of CYT-0851 with capecitabine was not identified. The dose escalation of CYT-0851 in combination with gemcitabine is ongoing and the study has cleared the 200 mg dose.

Combination of CYT-0851 with capecitabine

Combination of CYT-0851 with gemcitabine


About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Cyteir's current priority in CYT-0851 development is in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer. Follow Cyteir on social media: LinkedIn and Twitter and at www.cyteir.com.

Forward-Looking Statements

This press release contains "forward-looking statements" about Cyteir's strategy, future plans, and prospects, including statements regarding the development of CYT-0851, regulatory strategy and path for CYT-0851, and the expected timing and reporting of data for CYT-0851. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "likely," "may," "might," "plan," "potential," "project," "seek," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to: that Cyteir's clinical trials may fail to demonstrate adequately the safety and efficacy of CYT-0851; that preclinical testing of CYT-0851 may not be predictive of the results or success of clinical trials; that the clinical development of CYT-0851 may be delayed or otherwise take longer and/or cost more than planned; that Cyteir may be unable to initiate, enroll or complete clinical development of CYT-0851; that preliminary data may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data; that the continuing global outbreak of COVID-19 (including any resurgences or variants) may result in development or manufacturing delays, supply shortages, or shortages of qualified healthcare personnel; that synthetic lethality, as an emerging class of precision medicine targets, could result in negative perceptions of the efficacy, safety or tolerability of this class of targets, which could adversely affect our ability to conduct our business, advance our drug candidates or obtain regulatory approvals; and that Cyteir's compounds may not receive regulatory approvals or become commercially successful products. These and other risks and uncertainties are identified under the heading "Risk Factors" in Cyteir's most recent Annual Report on Form 10-K and other filings Cyteir has made and may make with the Securities and Exchange Commission ("SEC") in the future, available on the SEC's website at www.sec.gov.

The forward-looking statements contained in this press release are based on management's current views, plans, estimates, assumptions, and projections with respect to future events, and Cyteir does not undertake and specifically disclaims any obligation to update any forward-looking statements.

These press releases may also interest you

at 00:05
The ASTER_Wise Smart Community Theme Alliance has successfully brought together 13 Taiwanese manufacturers specializing in various fields such as smart sensors, information security protection, and online audio and video marketing. Their collective...

23 sep 2023
The retail market in Vietnam is estimated to grow by USD 163.49 billion from 2022 to 2027, growing at a CAGR of 11.4%. The retail market in Vietnam is fragmented owing to the presence of many global and regional companies. A few prominent companies...

23 sep 2023
At today's Global Citizen Festival, Give Lively, a ground-breaking nonprofit fundraising platform, and Shift4 , the leader in integrated payments and commerce technology, announced a partnership to the significant benefit of nonprofit organizations...

23 sep 2023
Oksana Chusovitina, a legendary artistic gymnast from Uzbekistan and a symbol of longevity in the sport, has set her sights on success at the Hangzhou Asian Games. "I want to compete in the Asian Games to demonstrate what I can do," the 48-year-old,...

23 sep 2023
Prepare to experience a laser engraving journey like never before as Monport Laser announces the expansion of its robust after-sales technical support services. With an unwavering dedication to exceeding customer expectations, Monport is now seeking...

23 sep 2023
Trip.com Group CEO Jane Sun today welcomed Italy's Minister of Tourism, Ms Daniela Santanchè, and her delegation, at the Group's office in Shanghai. Ms. Santanchè delegation included Ms. Erika Guerri, Head of Cabinet, Ms. Tiziana D'Angelo, Consul...

News published on and distributed by: